Immutep

Business Strategy


    ImmuFact® IMP321 Chemo-Immunotherapy

    The Company is seeking a partner to carry out the Phase IIb/III trial in first-line metastatic breast cancer leading to Conditional Marketing Authorisation and marketing. The partner will also initiate new studies in a wide range of cancers and different chemotherapies.


    ImmuTune® IMP701 Antagonist Antibody

    The Company is seeking partnerships to produce a human or humanized antibody and carry out clinical development.

» Business Opportunities
© 2002 Immutep, S.A.
Press Release
01/2011 - Immutep and GlaxoSmithKline sign licence agreement for IMP731, a novel therapeutic antibody for the treatment of autoimmune diseases
image Immutep S.A. announced today the execution of a licence agreement ...
09/2010 - Immutep announces final results in phase I/II chemoimmunotherapy trial in metastatic breast cancer.
image Clinical research paper describes IMP321’s potency in achieving ...
05/2010 - Immutep Announces Oral Presentation at ASCO Annual Meeting of IMP321 Final Results In Phase I/II Chemoimmunotherapy Trial
image Immutep S.A. announced today that the final results from its Phase ...
01/2010 - Interview Frederic Triebel with PharmaTelevision
01/2010 - ImmuFact IMP321 doubles clinical response rate in first-line metastatic breast cancer
image Immutep S.A. announced today the final results from its Phase I/II ...